Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.490
+0.010 (0.40%)
At close: May 13, 2026, 4:00 PM EDT
2.450
-0.040 (-1.61%)
After-hours: May 13, 2026, 7:43 PM EDT

Acumen Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.5118.9520.2218.8212.887.28
Research & Development
96.1104.8993.842.3232.3612.31
Total Operating Expenses
114.61123.83114.0261.1445.2419.58
Operating Income
-114.61-123.83-114.02-61.14-45.24-19.58
Interest Income
6.047.4514.3210.792.390.08
Interest Expense
-4.27-4.22-4.07-0.58--
Other Non-Operating Income (Expense)
-0.47-0.731.44-1.44-0.01-81.11
Total Non-Operating Income (Expense)
1.342.511.698.772.38-81.02
Pretax Income
-113.28-121.34-102.33-52.37-42.86-100.61
Net Income
-113.28-121.34-102.33-52.37-42.86-100.61
Net Income to Common
-113.28-121.34-102.33-52.37-42.86-100.61
Shares Outstanding (Basic)
616160494120
Shares Outstanding (Diluted)
616160494120
Shares Change (YoY)
1.73%0.91%23.46%19.72%102.43%-
EPS (Basic)
-1.86-2.00-1.71-1.08-1.06-5.02
EPS (Diluted)
-1.86-2.00-1.71-1.08-1.06-5.02
Shares Outstanding
72.2360.5860.0957.9141.0340.47
Free Cash Flow
-105.55-115.63-86.23-43.09-35.31-18
Free Cash Flow Per Share
-1.72-1.91-1.44-0.89-0.87-0.90
EBITDA
-114.43-123.65-113.84-60.95-45.07-19.58
EBIT
-114.61-123.83-114.02-61.14-45.24-19.58
Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q